HRT and Uterine Bleeding: What Every Woman Needs to Know

Why HRT Causes Uterine Bleeding

Exogenous estrogen stimulates endometrial proliferation. Without adequate progestogen opposition, the endometrium thickens, then sheds unpredictably. The addition of a progestogen limits that proliferative drive, but the dose, type, and timing of the progestogen determine whether bleeding is scheduled, irregular, or absent.

Most women starting a new HRT regimen experience some degree of irregular spotting or light bleeding during the first three to six months. This is not a sign of pathology. The endometrium is recalibrating to a new hormonal environment, and irregular shedding during that period is physiologically expected. A 2005 Cochrane review of continuous-combined versus sequential HRT found that unscheduled bleeding in the first six months occurred in up to 40% of continuous-combined users, compared with predictable scheduled withdrawal bleeds in nearly all sequential users. [1]

The distinction between an acceptable adjustment bleed and a clinically significant bleed depends on three variables: the timing relative to regimen initiation, the quantity and duration of blood loss, and whether the woman is postmenopausal or perimenopausal.

Continuous-Combined vs. Sequential HRT: Different Bleeding Profiles

The two main HRT architectures produce very different uterine responses, and matching the regimen to the patient's menopause stage reduces the risk of problematic bleeding.

Sequential (cyclical) HRT adds progestogen for 10 to 14 days per calendar cycle. The endometrium builds under estrogen, then sheds when the progestogen is withdrawn. Women get a predictable withdrawal bleed, usually lasting four to seven days, similar to a light period. This regimen suits perimenopausal women or those within 12 months of their last natural period, because their endometrium still expects a cycle. Unscheduled bleeding between the expected withdrawal phase, or bleeds heavier than a normal period, signal pathology that needs investigation.

Continuous-combined HRT delivers both estrogen and progestogen every day without a break. The aim is endometrial atrophy and eventual amenorrhea. Most women reach amenorrhea by month six to twelve, but the path there involves irregular spotting. Starting continuous-combined HRT too early in the menopause transition, before the endometrium has settled, dramatically increases the likelihood of persistent irregular bleeding. The Menopause Society recommends waiting at least 12 months after the final menstrual period before switching a woman to a continuous-combined regimen. [2]

A 2019 randomized trial published in Menopause comparing 17-beta estradiol plus micronized progesterone (continuous) against a norethisterone-containing comparator found that 58% of women on micronized progesterone were amenorrheic by month six, versus 71% on norethisterone, suggesting that synthetic progestins may actually produce faster endometrial atrophy despite other safety differences. [3]

When Uterine Bleeding on HRT Is a Red Flag

Most bleeding in the first six months is benign. However, certain patterns demand same-week investigation regardless of how long a woman has been on HRT.

Red-flag patterns include:

• Any vaginal bleeding that starts or restarts after 12 consecutive months of amenorrhea on continuous-combined HRT
• Bleeding heavier than a full normal period at any point on sequential HRT
• Spotting or bleeding that persists beyond month six on any regimen without improvement
• Postcoital bleeding
• Pelvic pain accompanying the bleeding

The investigation pathway typically starts with a transvaginal ultrasound to measure endometrial thickness. A thickness of 4 mm or less in a postmenopausal woman on HRT substantially reduces (though does not eliminate) the probability of endometrial carcinoma. An endometrial thickness above 4 mm warrants tissue sampling via endometrial biopsy or hysteroscopy. [4]

Endometrial cancer is the fourth most common cancer in women in the United States, with approximately 66,200 new cases projected for 2023 according to the National Cancer Institute. [5] The principal modifiable hormonal risk factor is unopposed estrogen exposure. Any woman with a uterus who takes systemic estrogen without progestogen opposition faces a substantially elevated endometrial cancer risk, with the relative risk rising from about 2-fold with one to two years of unopposed use to approximately 10-fold with more than 10 years of use. [6]

Progestogen addition eliminates that excess risk when used adequately. The key word is "adequately." Ten days of progestogen per cycle is minimally protective; 12 to 14 days per cycle provides reliable endometrial protection. [2]

The Role of the Progestogen Type in Bleeding and Safety

Not all progestogens behave the same way, and the choice between synthetic progestins and bioidentical micronized progesterone affects both the bleeding pattern and broader safety.

Synthetic progestins such as medroxyprogesterone acetate (MPA), norethisterone acetate (NETA), and levonorgestrel bind the progesterone receptor but also interact with androgen, glucocorticoid, and mineralocorticoid receptors to varying degrees. Micronized progesterone (Prometrium, Utrogestan) is structurally identical to endogenous progesterone and has a cleaner receptor profile.

From a bleeding standpoint, NETA and levonorgestrel tend to produce faster endometrial atrophy and quicker amenorrhea in continuous-combined regimens. Micronized progesterone produces slightly more irregular spotting in the first months but is associated with a more favorable cardiovascular and breast safety profile (see the breast cancer section below).

The E3N-EPIC cohort study (N=80,377) found that women using estrogen combined with synthetic progestins had a significantly higher risk of breast cancer than women using estrogen combined with micronized progesterone (relative risk 1.69 vs. 1.00 for estrogen-only, with micronized progesterone showing no significant excess risk). [7] That distinction matters when counseling a patient who is experiencing ongoing irregular bleeding and considering a progestogen switch.

A practical clinical decision framework:

1. Perimenopausal woman, uterus intact, irregular natural cycles. Use sequential HRT with 14 days of progestogen per cycle. Accept a withdrawal bleed. Investigate any unscheduled bleed.
2. Postmenopausal woman, 12 or more months of natural amenorrhea, uterus intact. Start continuous-combined HRT. Counsel for six months of potential spotting. Any bleeding after month 12 of amenorrhea requires same-week ultrasound.
3. Woman post-hysterectomy. Estrogen alone. No progestogen required. No endometrial bleeding risk.
4. Woman with ongoing breakthrough bleeding beyond month six on continuous-combined HRT. Assess endometrial thickness. If normal, consider switching progestogen type or increasing progestogen dose before changing to a levonorgestrel intrauterine system (Mirena), which delivers progestogen locally with near-zero systemic absorption and very high amenorrhea rates.

The levonorgestrel IUS deserves specific mention. A 2022 meta-analysis in Climacteric (12 RCTs, N=2,847) found that women using systemic estrogen plus the levonorgestrel IUS had amenorrhea rates of 78% to 94% at 12 months, superior to most oral progestogen regimens, with equivalent endometrial protection. [8]

Breast Cancer Risk: What the Evidence Actually Shows

Breast cancer risk is the single most common reason women decline or discontinue HRT, but the risk varies substantially by regimen type, and some formulations carry no measurable excess risk.

The Million Women Study (N=1,084,110) reported that current users of combined estrogen-progestogen HRT had a relative risk of breast cancer of 2.00 (95% CI 1.88 to 2.12) compared with never-users, while estrogen-only users had a relative risk of 1.30. [9] Those numbers alarmed clinicians and patients alike when published in 2003, but subsequent analysis revealed that the absolute excess risk for combined HRT was approximately 1.0 to 1.5 extra cases per 1,000 women per year of use, a risk comparable to drinking one to two alcoholic drinks daily.

The WHI randomized controlled trial (N=16,608) confirmed that estrogen plus MPA increased breast cancer incidence (HR 1.26 to 95% CI 1.00 to 1.59 at 5.6 years), while the estrogen-only arm (N=10,739 women with prior hysterectomy) showed a non-significant reduction in breast cancer risk (HR 0.77 to 95% CI 0.59 to 1.01). [10]

The French E3N-EPIC cohort, cited above, showed that micronized progesterone combined with estradiol carried no significant breast cancer excess. [7] A separate UK primary care database study published in The Lancet in 2019 (N=over 100,000) found that all progestogen-containing regimens raised breast cancer risk, but the excess was lowest with progesterone-based regimens and highest with norethisterone-based products. [11]

The Menopause Society's 2023 position statement states directly: "For healthy women younger than age 60 or within 10 years of menopause onset, the benefit-risk ratio of MHT is favorable for bothersome vasomotor symptoms." [2]

VTE and Stroke Risk: Route of Delivery Changes the Equation

Venous thromboembolism (VTE) and ischemic stroke are real risks with oral estrogen, but transdermal estrogen largely sidesteps them, a point that remains underappreciated in clinical practice.

Oral estrogen undergoes first-pass hepatic metabolism, increasing coagulation factors, reducing protein S, and raising C-reactive protein. Transdermal estrogen bypasses the liver and does not produce those hemostatic changes.

The ESTHER case-control study (N=881 cases, 1,452 controls) found that transdermal estradiol carried no significant VTE excess (odds ratio 0.9 to 95% CI 0.4 to 2.1), while oral estrogen raised VTE risk approximately 4-fold (OR 4.2 to 95% CI 1.5 to 11.6). [12] The TREATS study and several UK cohort analyses have replicated this finding.

For stroke, the WHI showed that oral conjugated equine estrogen 0.625 mg raised ischemic stroke risk by 44% (HR 1.44 to 95% CI 1.09 to 1.90). [13] A Danish population-based cohort study published in the British Medical Journal (N=980,003 women) found that transdermal and vaginal estradiol products were not associated with any increase in stroke risk, while oral estradiol and conjugated estrogen were associated with a small but significant excess risk. [14]

For women with baseline VTE risk factors, such as a personal history of DVT, obesity, or factor V Leiden mutation, current guidelines from the British Menopause Society recommend transdermal estrogen as first-line delivery. The type of progestogen matters too. Micronized progesterone and dydrogesterone appear to have a neutral or lower VTE profile compared with synthetic progestins. [15]

Dementia Risk: Timing Is Everything

The relationship between HRT and dementia has shifted considerably as researchers have moved away from the WHI's older-women data and toward studies in women who started HRT near menopause onset.

The WHI Memory Study (WHIMS), which enrolled women aged 65 to 79, found that combined estrogen-progestogen HRT doubled the risk of dementia (HR 2.05 to 95% CI 1.21 to 3.48). [16] That result, extrapolated incorrectly to younger perimenopausal women for years, drove widespread fear. The critical detail: those participants were on average 72 years old at enrollment, far outside the window when estrogen's neuroprotective actions appear to operate.

The "critical window" or "timing hypothesis" holds that estrogen initiated within approximately five to ten years of menopause onset, while neurons still express adequate estrogen receptors and amyloid burden is low, may reduce the risk of Alzheimer-type dementia. Estrogen started two decades after menopause, into a brain already showing neurodegenerative change, appears either neutral or harmful.

A 2021 observational study from the UK Biobank (N=14,706 postmenopausal women) found that HRT use was associated with better verbal declarative memory scores (beta 0.09, P<0.01), with the strongest effects in women who started before age 60. [17] The CACHE County Study similarly found that women who used HRT within five years of menopause had a significantly lower hazard of Alzheimer's disease (HR 0.59 to 95% CI 0.36 to 0.96). [18]

Women with premature ovarian insufficiency (POI), defined as menopause before age 40, face a particularly elevated dementia risk if HRT is not started promptly, because they experience decades of estrogen deficiency during a vulnerable neurological window. Current guidelines from the European Menopause and Andropause Society recommend HRT until at least the average age of natural menopause (51 years) in women with POI. [19]

Current clinical guidance does not support prescribing HRT specifically for dementia prevention in average-risk postmenopausal women. The evidence is observational, not from RCTs with cognitive endpoints, and confounding remains a major concern.

Managing Ongoing Breakthrough Bleeding: Practical Steps

When a patient calls about persistent or unexpected bleeding on HRT, the clinical approach follows a clear sequence.

First, establish the timeline. Bleeding before month six on a continuous-combined regimen that is light and improving is almost certainly an adjustment response. Document it, reassure, and review at three months. Bleeding that is heavy from the start, worsening, or present after six months demands investigation.

Second, check adherence and timing. Missed doses of progestogen, or taking progestogen inconsistently, produce unpredictable endometrial shedding. Even one or two missed doses per cycle can destabilize the endometrium and cause breakthrough bleeding.

Third, rule out non-hormonal causes. Cervical polyps, cervical ectropion, fibroids, and cervical carcinoma all cause intermenstrual or postcoital bleeding independent of HRT. A speculum examination is mandatory before attributing ongoing bleeding to the HRT regimen.

Fourth, measure endometrial thickness. If the endometrium is atrophic (typically below 4 mm on transvaginal ultrasound), the bleeding is almost certainly benign and a progestogen adjustment usually resolves it. If thickness is above 4 mm or if the endometrial echo looks irregular, refer for hysteroscopy and biopsy.

Fifth, consider regimen adjustment. Options include increasing the progestogen dose, extending the progestogen phase from 10 to 14 days (in sequential users), switching from oral to intrauterine progestogen delivery, or switching progestogen type. A clinical trial published in Menopause (N=312) found that switching from oral MPA to a levonorgestrel IUS reduced unscheduled bleeding episodes by 83% over 12 months while maintaining equivalent endometrial protection. [20]

HRT After Hysterectomy: Simpler but Not Risk-Free

Women who have had a hysterectomy have no uterus and no endometrial cancer risk, so progestogen is not needed. Estrogen-only HRT carries a cleaner breast cancer risk profile than combined regimens and, per the WHI estrogen-only trial, may even reduce breast cancer incidence. VTE and stroke risk still follow the oral-versus-transdermal split described above.

The absence of bleeding as a monitoring endpoint in hysterectomized women means that other safety surveillance, primarily mammography, blood pressure monitoring, and lipid panels, takes on greater importance. Routine pelvic exams remain appropriate to assess vaginal atrophy, pelvic floor function, and ovarian status if the ovaries were retained.